The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

A key advisory group vows to base decisions on evidence, boost confidence in vaccines and protect health. Experts fear the opposite is happening.

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60.

Vaxcyte Inc. (NASDAQ:PCVX) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June ...

OP-ED. The US secretary of health has completely overhauled the national committee of vaccination experts, appointing ...

The US appears to be turning its back on a scientific consensus that has relegated several diseases to history ...

The U.S. Centers for Disease Control and Prevention (CDC) has accepted recommendations from an advisory panel that endorsed ...

A majority upheld part of the process used to create the package, but a Mercer analyst says there's more to the story.

The decision shows just how vaccine critics are beginning to shape official U.S. policy, public health officials told The Washington Post.

There are guardrails in the U.S. health system intended to prevent recommended vaccines from being prohibitively expensive.

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...